Dasatinib therapy for CML patients unsuitable for imatinib
14 Jul 2011
Dasatinib therapy for CML patients unsuitable for imatinib
VTD consolidation therapy for multiple myeloma
Patient non-compliance to treatment schedules
Development of lenvatinib for thyroid cancer
Health care issues in low and middle income countries.
Clinical research at Sarah Cannon UK
Research from the Sarah Cannon Research Institute
Role of vemurafenib in melanoma treatment
The changing landscape of melanoma therapies: indications of better patient outcome
Standard of care for ovarian cancer
Treatment options for ovarian cancer
2011 Gianni Bonadonna Breast Cancer Award and ASCO breast highlights